Previous 10 | Next 10 |
Summary Despite recent clinical and regulatory wins, bluebird bio's commercial success remains highly uncertain. Competition from next-generation gene therapies is closing in on lovo-cel (for Sickle Cell Disease), making a commercial success (if any) short-lived. Zynteglo's la...
Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...
This study will evaluate Abecma in patients with suboptimal response to transplant Data from KarMMa-3 and KarMMa-2 studies of Abecma will be presented at future medical meeting 2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa...
Abecma, a CAR-T myeloma therapy, is rapidly ramping revenue. 2seventy has $398 million in cash. Multiple advanced T-cell platforms could generate many more successful therapies. 2seventy bio ( TSVT ) was spun off from bluebird bio ( BLUE ) in November 2021. It st...
2seventy bio press release ( NASDAQ: TSVT ): Q2 GAAP EPS of -$2.02 misses by $0.09 . Revenue of $13.48M (+83.9% Y/Y) misses by $3.04M . Ended quarter with $399M cash, cash equivalents, and marketable securities; revising 2022 net cash spend to $245-265M; mainta...
Bristol Myers Squibb ( NYSE: BMY ) and its partner 2seventy bio ( TSVT ) announced on Wednesday that a Phase 3 trial for Abecma a CAR T cell therapy they jointly develop reached the main goal in certain adult patients with multiple myeloma. 2seventy bio ( TSVT ) adde...
ABECMA generated $ 72M U.S. commercial revenue in 2Q; continues to track toward upper end of $250-$300M revenue guidance for 2022 Results from prespecified interim analysis of KarMMa-3 trial shows ABECMA (idecabtagene vicleucel) significantly improves progression-free ...
Abecma is the first BCMA-directed CAR T cell therapy to demonstrate superiority versus standard regimens in relapsed and refractory multiple myeloma Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced positive topline results fr...
2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: 2022 Wedbush PacGrow Healthcare Conference, “A View to a Kill(er Cell) – Part 1” panel on Wednesday, Aug...
For further details see: Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate
News, Short Squeeze, Breakout and More Instantly...
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...
2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...